Jørgensen, Heather G and Allan, Elaine K and Mountford, Joanne C and Richmond, Linda and Harrison, Simon and Elliott, Moira A and Holyoake, Tessa L (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-6. ISSN 0301-472X
Full text not available in this repository. (Request a copy from the Strathclyde author)Official URL: http://dx.doi.org/10.1016/j.exphem.2005.05.020
Abstract
In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.
| Item type: | Article |
|---|---|
| ID code: | 32632 |
| Keywords: | antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines, Therapeutics. Pharmacology, Neoplasms. Tumors. Oncology (including Cancer) |
| Subjects: | Medicine > Therapeutics. Pharmacology Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer) |
| Department: | Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences |
| Related URLs: | |
| Depositing user: | Pure Administrator |
| Date Deposited: | 19 Aug 2011 21:05 |
| Last modified: | 04 Oct 2012 13:49 |
| URI: | http://strathprints.strath.ac.uk/id/eprint/32632 |
Actions (login required)
| View Item |